We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Trials of drugs targeting complicated intra-abdominal infections should use only drugs that are standard of care as active comparators, the FDA says, and studies should minimize the use of outside antibiotics in trial subjects as much as possible to produce clear, definitive trial results. Read More
An FDA advisory committee will meet next month to consider Celltrion’s biosimilar version of Janssen’s Remicade, putting the agency on track to meet a goal of reviewing five biosimilar applications a year. Read More
Despite gain in recent years, venture funding for pharmaceutical innovation still lags behind prerecession levels, according to a new BIO report that also tracked a move away from developing novel therapies in favor of improving on existing ones. Read More
A proposal to lift restrictions on how drugmakers can promote products on social media and another that would grant up to 15 years of generics-free exclusivity to drugs approved to treat an unmet medical need are emerging as controversial issues in a proposal to overhaul FDA drug approval processes. Read More
The FDA barred beleaguered drugmaker Ipca Laboratories from shipping drugs to the U.S because of good manufacturing practice violations — the 27th time the agency has cracked down on GMP violations at Indian drug facilities in the last two years. Read More
In a 46-page draft guidance, the FDA clarified a 2013 final rule that specifies how combination product manufacturers should meet both device and drug quality regulations and implement streamlined quality systems. Read More